)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Uniphar
Uniphar (UPR) investor relations material
Uniphar H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary8 Sep, 2026
Executive summary
Delivered strong H1 2026 results with 7.2% revenue growth to €1.59bn, 7.7% gross profit growth to €236.5m, and 6.2% EBITDA growth to €61.1m, with all divisions contributing robust organic growth.
Adjusted EPS increased by 11.2% to 10.9 cent; ROCE reached 14.7%, within the 12%-15% target range.
Strategic investments in infrastructure and technology are underway to support long-term growth and scalability.
On track to achieve €200 million EBITDA by 2028, with at least 80% of growth expected to be organic, driven by organic growth and selective M&A.
Financial highlights
Revenue rose to €1,591.9m, gross profit to €236.5m, and EBITDA to €61.1m, with gross profit margin stable at 14.9%.
Adjusted EPS up 11.2% to 10.9 cent; basic EPS up 16.7% to 7.7 cent.
Net bank debt at €275.7m, leverage at 2.4x, reflecting working capital unwind and capital investment.
Free cash flow conversion was -77.1% for H1 2026 due to working capital timing, but five-year average is 65%.
Interim dividend of €0.0074 per share declared, up 4.2%.
Outlook and guidance
Confident in double-digit Pharma growth for the full year, high single-digit MedTech growth, and mid-single digit Supply Chain & Retail growth.
EBITDA growth expected to accelerate in H2 2026; on track for €200m EBITDA by 2028, with FCF conversion expected to normalize to 60%-70%.
Net bank debt/EBITDA to remain below 2.5x in the medium term.
M&A remains a strategic enabler, with focus on Pharma and MedTech platforms.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Uniphar
- Adjusted EPS up 11% in H1 2026, with robust growth and strong liquidity maintained.UPR
H1 2026 TU - Strong organic growth, robust cash flow, and infrastructure investment drive 2028 targets.UPRH2 2025
- Achieved 21% adjusted EPS growth in 2025, with strong organic profit and positive 2026 outlook.UPRH2 2025 TU
- Strong H1 2025 growth, 8.1% organic profit, 21% EPS rise, and €35m buyback.UPRH1 2025
- Revenue up 10.3%, EBITDA up 6.3%, and all divisions delivered strong growth.UPRH1 2024
- Gross profit up 9.6%, EBITDA €123.5m, and a €35m share buyback announced for 2024.UPRH2 2024
Next Uniphar earnings date
H2 202623 Feb, 2027
Uniphar
Next Uniphar earnings date
H2 202623 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Uniphar Public Limited Company is a diversified healthcare services provider, operating mainly in the Republic of Ireland, the United Kingdom, and on an international scale. The company functions through three primary divisions: Commercial & Clinical, Product Access, and Supply Chain & Retail. In the Commercial & Clinical segment, Uniphar offers outsourced sales, marketing, and multichannel account management services to pharmaco-medical manufacturers, alongside distribution and support services to medical device manufacturers. The Product Access division delivers services that facilitate access to pharmaco-medical products and treatments, establishing vital connections between manufacturers and healthcare stakeholders, as well as providing bespoke distribution partnerships for pharmaceutical partners. The Supply Chain & Retail division is involved in the pre-wholesale and wholesale distribution of pharmaceutical, healthcare, and animal health products to pharmacies, hospitals, and veterinary surgeons, and operates a network of pharmacies under various brands. Additionally, it provides a range of support services including pharmacy support, specialist nursing, infusion, medical device distribution, healthcare technology, data intelligence, consultancy, pharmaceutical advisory, medical affairs, online pharmacy, and product fostering services. The company is headquartered in Dublin, Ireland, and its shares are listed on the Irish Stock Exchange.